{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014813","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.877804+00:00","generated_at":"2026-05-15T07:46:41.022919+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Elite Pharmaceuticals launches generic methadone tablets; addresses $22M market","bullets":["Launched generic methadone HCl 5 mg and 10 mg tablets under Elite Laboratories label.","Product indicated for severe persistent pain and opioid addiction detoxification/maintenance treatment.","Annual retail sales for brand and generic methadone tablets approx. $22M (IQVIA 2025 data).","Company operates a cGMP and DEA-registered R&D and manufacturing facility in Northvale, NJ."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014813","json":"https://secwatch.observer/filing/0001493152-26-014813.json","markdown":"https://secwatch.observer/filing/0001493152-26-014813.md","text":"https://secwatch.observer/filing/0001493152-26-014813.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226014813/0001493152-26-014813-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226014813/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:46:41.022919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}